We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Fluorimetric Assay Quantifies Galactocerebrosidase Activity in Dried Blood Spots

By LabMedica International staff writers
Posted on 29 Oct 2019
The lysosomal enzyme galactocerebrosidase hydrolyzes glycosidic bonds of several glycosphingolipids, including galactose from galactosylsphingosine (psychosine), and is essential to prevent the toxic accumulation of psychosine in the body.

Decreased galactocerebrosidase (GALC) enzyme activity is causative for Krabbe disease, a lysosomal storage disorder with devastating neurodegenerative consequences. More...
Quantitative fluorimetric assays for GALC activity in isolated blood and skin cells have been described, but not for dried blood spots specimens (DBS).

A team of scientists from the commercial company Baebies, Inc (Durham, NC, USA) and Duke University (Durham, NC, USA) developed a rapid, microtiter plate fluorimetric assay for measuring GALC enzyme activity in DBS specimens using a novel substrate: β-galactose conjugated with a fluorogenic derivative of 6-hexadecanoyl-4-methylumbelliferone with a hydrophobic group.

Samples were obtained as individual punches (3.2 mm diameter) from DBS cards of presumed normal newborns. Archived, deidentified DBS from 10 affected Krabbe disease patients were obtained from the Legacy of Angels Foundation. To extract galactocerebrosidase enzyme from the DBS samples, one punch (3.2 mm) from each DBS was placed in individual wells of a clear, round-bottom, 96-well microtiter plate.

Sample extraction solution (100 μL) was added to each sample well; the plate was covered with a clear adhesive sealer to prevent evaporation and then incubated on a plate-shaker (600 rpm) at room temperature (RT) for 30 minutes. Enzyme activity was determined by adding 10 μL of DBS extract to 10 μL of the GALC substrate solution, which was varied. The fluorescence of the plate, measured as relative fluorescence units (RFU), was read in a Synergy HTX microtiter plate reader with 400 ±15 nm excitation and 485 ±20 nm emission filters.

The GALC assay was carefully optimized to ensure robust performance from the small amount of enzyme present in DBS and to minimize interference from β-galactosidase. The team found that the linear range of the fluorimetric GALC assay encompassed the entire range of samples tested. The activity in the presumed normal samples shows a wide range (0.39 – 15.6 μmol/L/hour) with a population mean of 2.108 μmol/L/hour. As expected, GALC activity in the affected samples is significantly lower than in the presumed normal samples.

The authors concluded that a fluorimetric assay for GALC enzyme activity measurement on dried blood spot specimens is feasible. Improvements to the assay including novel substrate design, increased substrate concentration and removal of sodium chloride maximize the specificity of the assay and minimize interference from β-galactosidase. The study was published on October 16, 2019, in the journal Practical Laboratory Medicine.

Related Links:
Baebies
Duke University


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Portable POCT Blood Gas Analyzer
BD100
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: iStock

AMP 2026 Underscores Molecular Testing’s Role in Precision Medicine for Women’s Health

Advances in molecular diagnostics are creating new opportunities to improve the detection of sexually transmitted infections, identify antibiotic resistance, and assess cancer recurrence risk in women.... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.